Your browser is no longer supported. Please, upgrade your browser.
CALT Calliditas Therapeutics AB (publ) daily Stock Chart
Calliditas Therapeutics AB (publ)
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand23.97M Perf Week5.06%
Market Cap559.56M Forward P/E- EPS next Y-0.04 Insider Trans- Shs Float22.56M Perf Month16.96%
Income- PEG- EPS next Q-0.40 Inst Own- Short Float0.02% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.04 Perf Half Y-
Book/sh- P/B- EPS next Y96.60% ROA- Target Price40.00 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range19.00 - 24.97 Perf YTD19.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-6.51% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low22.87% ATR1.15
Employees17 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility5.83% 4.41%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.04 Prev Close23.78
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume99.27K Price23.34
Recom1.00 SMA2012.20% SMA5012.94% SMA20012.94% Volume3,520 Change-1.83%
Jul-01-20Initiated Citigroup Buy $36
Jun-30-20Initiated Jefferies Buy $44
Jun-25-20 12:53PM  
Jun-24-20 10:17PM  
Jun-12-20 07:15PM  
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.